Rigel Pharmaceuticals (RIGL) News
NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.09-1.10 (-2.67%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RIGL news summary
We found 6 recent headlines mentioning Rigel Pharmaceuticals (RIGL): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, PR Newswire, Seeking Alpha. For price context, RIGL is down 2.67% at $40.09. The most recent story, "Rigel to Present at the Jefferies Global Healthcare Conference in London", was published by PR Newswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Rigel Pharmaceuticals headlines
- Rigel to Present at the Jefferies Global Healthcare Conference in LondonSOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today…PR Newswire
- Rigel (RIGL) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Rigel Pharmaceuticals GAAP EPS of $0.70 misses by $0.18, revenue of $80.9M beats by $0.8MSeeking Alpha
- United Therapeutics (UTHR) Q3 Earnings Miss EstimatesUnited Therapeutics (UTHR) delivered earnings and revenue surprises of -2.39% and +6.28%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the…NasdaqUTHR, RIGL
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close…PR Newswire
- Reasons Why Investors Should Consider Betting on Arvinas StockARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.NasdaqARVN, PFE, RIGL